Table 2.
The different response rates of BRCA-wild TNBC patients treated with platinum-based chemotherapy between with high and with low HRD score.
| Author | Year | Study design | Responders | HRD score ≥ 42 | HRD score < 42 | P value |
|---|---|---|---|---|---|---|
| Richardson et al.45 | 2014 | Cisplatin-containing neoadjuvant chemotherapy | pPR | 10 (52.6%) | 2 (10.5%) | 0.0039 |
| pCR | 5 (26.3%) | 0 (0%) | 0.018 | |||
| Kaklamani et al. 47 | 2015 | Carboplatin-containing neoadjuvant chemotherapy | pCR | 6 (66.7%) | 2 (14.2%) | 0.0016 |
| Von Minckwitz et al.66 | 2015 | Carboplatin-containing neoadjuvant chemotherapy | pCR | 41 (49.4%) | 17 (30.9%) | 0.05 |
| Tutt et al.68 | 2015 | carboplatin monotherapy in metastatic setting | Response rate | 31(38.2%) | 33(29.2%) | NA |
NA: Not available. pCR: pathologic complete response.